Tune Therapeutics vs Insilico Medicine
Side-by-side comparison of AI visibility scores, market position, and capabilities
Epigenome editing company silencing disease-causing genes without permanent DNA cuts; raised $175M Series B led by Hevolution, NEA, and Regeneron Ventures; dosed first patient in Phase 1/2 for chronic hepatitis B with Tune-401.
About
Tune Therapeutics is an epigenome editing company that silences disease-causing genes without making permanent DNA cuts — a potentially safer approach than traditional gene editing for chronic diseases. The company raised $175 million in Series B financing led by Hevolution Foundation (the world's largest longevity-focused philanthropic fund), NEA, and Regeneron Ventures, and has dosed its first patient in Phase 1/2 clinical trials for Tune-401, targeting chronic hepatitis B.
Insilico Medicine (HKEX: 3696) raised $293M, posted $56.2M revenue in 2025, and inked a $2.75B Eli Lilly deal in 2026 using generative AI to discover drug targets in cancer and CNS.
About
Insilico Medicine is a clinical-stage biotechnology company founded in 2014 that leverages generative AI for drug discovery and development. Headquartered in Boston with offices in Hong Kong and New York, the company has built AI platforms utilizing deep generative models, reinforcement learning, and transformers to discover novel drug targets and generate molecular structures with desired properties. Its pipeline spans cancer, fibrosis, CNS diseases, infectious diseases, autoimmune conditions, and aging-related diseases.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.